Clinical significance of Stathmin1 expression and epithelial‑mesenchymal transition in curatively resected gastric cancer

Ke,Bin; Guo,Xiao‑Fan; Li,Ning; Wu,Liang‑Liang; Li,Bin; Zhang,Ru‑Peng; Liang,Han

doi:10.3892/mco.2018.1774

Clinical significance of Stathmin1 expression and epithelial‑mesenchymal transition in curatively resected gastric cancer

Authors:
- Bin Ke
- Xiao‑Fan Guo
- Ning Li
- Liang‑Liang Wu
- Bin Li
- Ru‑Peng Zhang
- Han Liang
View Affiliations

Affiliations: Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: November 26, 2018 https://doi.org/10.3892/mco.2018.1774
Pages: 214-222
Copyright: © Ke et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In our previous study, it was demonstrated that the Stathmin1 (STMN1) is overexpressed in gastric cancer (GC) and that its high expression level is associated with tumor invasion and metastasis. Epithelial‑mesenchymal transition (EMT) has also been shown to be critically involved in GC invasion and metastasis. Certain studies have indicated that STMN1 may serve an important role in the EMT process. However, the association between STMN1 expression and EMT‑associated markers, as well as clinicopathological characteristics of patients with GC, remains unclear. The aim of the present study was to investigate the clinicopathological significance and prognostic value of STMN1 and EMT‑associated markers in GC. The expression of STMN1 and the EMT‑associated proteins E‑cadherin (E‑Cad) and vimentin (VIM) were analyzed by immunohistochemistry in GC and adjacent non‑tumorous tissues. Associations between the expression of these markers and clinicopathological parameters were analyzed. The association between STMN1 expression and EMT‑associated markers was investigated in the GC cell lines BGC‑803 and SGC‑7901. The results revealed that STMN1 was expressed in 63.5% of the 167 GC tissues, which was significantly higher than the percentage observed in the adjacent non‑tumorous tissues (P=0.003). The STMN1 expression was demonstrated to be positively associated with the VIM levels (P=0.001) and negatively associated with the E‑Cad levels (P=0.022) in GC tissues. The STMN1 expression was associated with Lauren's Classification, invasion depth, lymph node metastasis and pathological Tumor‑Node‑Metastasis (pTNM) stage (P<0.05). In the univariate analyses, the high E‑Cad expression was a positive prognostic indicator for overall survival, whereas the high STMN1 and VIM expression was a negative indicator. COX multiple regression analysis demonstrated that the pTNM stage [hazard ratio (HR) 1.912, 95% confidence interval (CI): 1.282‑2.851, P=0.001] and E‑Cad expression (HR 0.403, 95% CI: 0.249‑0.650, P=0.000) were independent prognostic factors. It was also revealed that the expression level of E‑Cad decreased, while the expression level of VIM increased by depleting STMN1 levels in GC cells. The present results suggest that the aberrant expression of STMN1 may promote tumor progression through EMT in GC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Digklia A and Wagner AD: Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 22:2403–2414. 2016. View Article : Google Scholar : PubMed/NCBI
3	Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, Schmidt C, Weber SM, Votanopoulos K, Maithel SK and Pawlik TM: Rates and patterns of recurrence after curative intent resection for gastric cancer: A United States multi-institutional analysis. J Am Coll Surg. 219:664–675. 2014. View Article : Google Scholar : PubMed/NCBI
4	Belletti B and Baldassarre G: Stathmin: A protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets. 15:1249–1266. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hemdan T, Linden M, Lind SB, Namuduri AV, Sjöstedt E, de Ståhl TD, Asplund A, Malmström PU and Segersten U: The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer. Br J Cancer. 111:1180–1187. 2014. View Article : Google Scholar : PubMed/NCBI
6	Shimizu K, Ohtaki Y, Altan B, Yokobori T, Nagashima T, Arai M, Mogi A and Kuwano H: Prognostic impact of stathmin 1 expression in patients with lung adenocarcinoma. J Thorac Cardiovasc Surg. 154:1406–1417.e3. 2017. View Article : Google Scholar : PubMed/NCBI
7	Suzuki S, Yokobori T, Altan B, Hara K, Ozawa D, Tanaka N, Sakai M, Sano A, Sohda M, Bao H, et al: High stathmin 1 expression is associated with poor prognosis and chemoradiation resistance in esophageal squamous cell carcinoma. Int J Oncol. Mar 7–2017.(Epub ahead of print). View Article : Google Scholar
8	Tian FJ, Qin CM, Li XC, Wu F, Liu XR, Xu WM and Lin Y: Decreased stathmin-1 expression inhibits trophoblast proliferation and invasion and is associated with recurrent miscarriage. Am J Pathol. 185:2709–2721. 2015. View Article : Google Scholar : PubMed/NCBI
9	Tseng YH, Huang YH, Lin TK, Wu SM, Chi HC, Tsai CY, Tsai MM, Lin YH, Chang WC, Chang YT, et al: Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma. Sci Rep. 6:387562016. View Article : Google Scholar : PubMed/NCBI
10	Wang J, Yao Y, Ming Y, Shen S, Wu N, Liu J, Liu H, Suo T, Pan H, Zhang D, et al: Downregulation of stathmin 1 in human gallbladder carcinoma inhibits tumor growth in vitro and in vivo. Sci Rep. 6:288332016. View Article : Google Scholar : PubMed/NCBI
11	Ke B, Wu LL, Liu N, Zhang RP, Wang CL and Liang H: Overexpression of stathmin 1 is associated with poor prognosis of patients with gastric cancer. Tumour Biol. 34:3137–3145. 2013. View Article : Google Scholar : PubMed/NCBI
12	Micalizzi DS, Farabaugh SM and Ford HL: Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
13	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
14	Creighton CJ, Chang JC and Rosen JM: Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 15:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
15	Kang Y and Massagué J: Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
16	Huang L, Wu RL and Xu AM: Epithelial-mesenchymal transition in gastric cancer. Am J Transl Res. 7:2141–2158. 2015.PubMed/NCBI
17	Zhang H, Liu J, Yue D, Gao L, Wang D, Zhang H and Wang C: Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol. 66:937–945. 2013. View Article : Google Scholar : PubMed/NCBI
18	Li N, Jiang P, Du W, Wu Z, Li C, Qiao M, Yang X and Wu M: Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci USA. 108:12851–12856. 2011. View Article : Google Scholar : PubMed/NCBI
19	Williams K, Ghosh R, Giridhar PV, Gu G, Case T, Belcher SM and Kasper S: Inhibition of stathmin1 accelerates the metastatic process. Cancer Res. 72:5407–5417. 2012. View Article : Google Scholar : PubMed/NCBI
20	Liu J, Cao J and Zhao X: miR-221 facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human bladder cancer cells by targeting STMN1. BMC Urol. 15:362015. View Article : Google Scholar : PubMed/NCBI
21	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumors. 7th. Wiley-Blackwell; Oxford: 2010
22	Gao Y, Niu Y, Wang X, Wei L, Zhang R, Lv S, Yu Q and Yang X: Chromosome aberrations associated with centrosome defects: A study of comparative genomic hybridization in breast cancer. Human Pathol. 42:1693–1701. 2011. View Article : Google Scholar
23	Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G and Gao Q: Lupeol induces apoptosis and cell cycle arrest of human osteosarcoma cells through PI3K/AKT/mTOR pathway. Technol Cancer Res Treat. 15:NP16–NP24. 2016. View Article : Google Scholar : PubMed/NCBI
24	Xia P and Xu XY: Epithelial-mesenchymal transition and gastric cancer stem cell. Tumour Biol. 39:10104283176983732017. View Article : Google Scholar : PubMed/NCBI
25	Peng Z, Wang CX, Fang EH, Wang GB and Tong Q: Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. World J Gastroenterol. 20:5403–5410. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lu Y, Liu C, Xu YF, Cheng H, Shi S, Wu CT and Yu XJ: Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition. Hepatobiliary Pancreat Dis Int. 13:386–394. 2014. View Article : Google Scholar : PubMed/NCBI
27	Jeon TY, Han ME, Lee YW, Lee YS, Kim GH, Song GA, Hur GY, Kim JY, Kim HJ, Yoon S, et al: Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer. 102:710–718. 2010. View Article : Google Scholar : PubMed/NCBI
28	Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW, Wong N, Yu J, Cheng AS and To KF: Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One. 7:e339192012. View Article : Google Scholar : PubMed/NCBI
29	De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, Gespach C, Bracke M and Berx G: Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol. 130:481–494. 2008. View Article : Google Scholar : PubMed/NCBI
30	Zhang J, Chen XY, Huang KJ, Wu WD, Jiang T, Cao J, Zhou LS, Qiu ZJ and Huang C: Expression of FoxM1 and the EMT-associated protein E-cadherin in gastric cancer and its clinical significance. Oncol Lett. 12:2445–2450. 2016. View Article : Google Scholar : PubMed/NCBI
31	Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I and Miceli R: Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer. 19:412–420. 2016. View Article : Google Scholar : PubMed/NCBI
32	Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY, Liang AB and Zeng HZ: CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci. 13:6399–6406. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ, Du H, Zhang GG, Hu Y, Lu AP, Li JY and Ji JF: Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology. 52:560–568. 2008. View Article : Google Scholar : PubMed/NCBI
34	Wu Y, Yamada S, Izumi H, Li Z, Shimajiri S, Wang KY, Liu YP, Kohno K and Sasaguri Y: Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J Surg Oncol. 105:724–730. 2012. View Article : Google Scholar : PubMed/NCBI
35	Kim MA, Lee HS, Lee HE, Kim JH, Yang HK and Kim WH: Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology. 54:442–451. 2009. View Article : Google Scholar : PubMed/NCBI
36	Wang ZS, Shen Y, Li X, Zhou CZ, Wen YG, Jin YB and Li JK: Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric cancer. Tumour Biol. 35:1357–1363. 2014. View Article : Google Scholar : PubMed/NCBI
37	Yang Y, Zhang J, Yan Y, Cai H, Li M, Sun K, Wang J, Liu X, Wang J and Duan X: Low expression of Rap1GAP is associated with epithelial-mesenchymal transition (EMT) and poor prognosis in gastric cancer. Oncotarget. 8:8057–8068. 2017.PubMed/NCBI